Navigation Links
Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
Date:5/14/2008

CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that the results from its Phase II coronary revascularization trial have been published in the peer-reviewed EuroIntervention Journal. The paper is entitled "Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularization. Rationale, protocol design, and haemodynamic results." The manuscript was authored by principal investigator Patrick W. Serruys, MD, PhD and colleagues of the Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.

"Biopure's COR-0002 study in the EuroIntervention Journal demonstrates the potential use of Hemopure (HBOC-201) in patients with coronary artery disease," said Biopure Chairman and CEO Zafiris G. Zafirelis. "Based on the efficacy and safety of the drug in this trial, we believe that Hemopure could be an oxygen bridge to prevent permanent myocardial damage in patients sustaining a heart attack."

The COR-0002 trial is a single-blind, open-label, single-center, cross- over pilot study where subjects underwent coronary balloon occlusion, with and without oxygenated HBOC-201. The primary objective of the study was to test the hypothesis that intracoronary infusion of HBOC-201 during brief, total coronary artery occlusion would preserve left ventricular function. The primary endpoints in COR-0002 were left ventricular diastolic relaxation indices as assessed by left ventricular pressure-volume loops and ST segment changes as assessed via electrocardiograms.

The study concluded that HBOC-201 was indeed capable of preserving left ventricular function, likely through mainte
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Biopure Reports on Meeting with the FDA
2. Biopure Announces 2007 Third Quarter Financial Results
3. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
4. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
5. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
6. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
7. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
8. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
9. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
10. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...MOUNTAIN VIEW, Calif., July 24 /PRNewswire-FirstCa... ) announced today that it has initiated,its secon...loxapine).,AZ-004 is an inhalation product candida...ation in patients with schizophrenia or bipolar di...ture and rapid pharmacokinetic,(PK) properties res...
(Date:7/24/2008)...WASHINGTON, July 24 /PRNewswire-USNewswire/ -- Hea...o not tell the whole story. The small scale,preli...line in Human,Reproduction, is based on recollecte...taining soyfoods. "This study is confounded by man... with a great deal of,caution," warned Dr. Tammy H...
(Date:7/24/2008)...Revolutionary thermometer designed to take body te...., July 24 /-- Kidz-Med, In...c. Pink Sheets: ASFX),United States distributor o...r, is pleased to announce the results of a clinica...of the University of Milan, in,Milan, Italy, which...
(Date:7/24/2008)...SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-Firs...nnounced the top-line results from the 52-week,ope...ing the completion of,the 301 phase 3 study for na...ty findings and efficacy was maintained for the on...atients, global assessment scale. In,addition, the...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Diagnostic Imaging New Stock Symbol OTCBB 3A DIIG 3077 1Diagnostic Imaging New Stock Symbol OTCBB 3A DIIG 3077 2Diabetes Growth Disorders Drive Sales of Pediatric Hormone Drugs 11166 1Diabetes Growth Disorders Drive Sales of Pediatric Hormone Drugs 11166 2New study suggests link between environmental toxins and early onset puberty in girls 11163 1New study suggests link between environmental toxins and early onset puberty in girls 11163 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 1Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 3Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 4
...ropean Hematology,Association (EHA) -, VIENNA, Aus...nomedics, Inc. , a biopharmaceutical company focus...ncer and other serious,diseases, today announced t...Vienna, Austria, showed positive responses in pati...h a new,radioimmunotherapy (RAIT) using epratuzuma...
...007 - Geron,Corporation (Nasdaq:GERN) today announ...g that GRNOPC1, the company,s human,embryonic stem...f,spinal cord injury, evades a direct attack by th...st Ross Okamura at the Federation of,Clinical Immu...s,could mean that patients treated with GRNOPC1 wo...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
(Date:7/25/2008)...s of Marketing Exclusivity Begins -, CORONA, Cali...aceuticals, Inc. (NYSE: WPI ), a leading specialt... subsidiary has commenced commercial,shipment of i... in the 40mg,strength from its Davie, Florida manu..., Watson has 180 days of marketing exclusivity for...
(Date:7/25/2008)...ion Executive, Robert J. Reilly, Joins Aethon Team...,( http://www.aethon.com ), the leading developer ...tics, today announced that Robert J. Reilly has,jo... Financial Officer., Reilly, who was most recentl...orporation,s Specialty Pharmacy Division, brings m...
(Date:7/25/2008)...ewswire/ -- The Elekta Family of Companies will,sh...ions at the 2008,American Association of Physicist... how the joint forces of Elekta, IMPAC and CMS are...g and delivery solutions that,streamline the treat...ients, as well as enhance clinician efficiency., ...
(Date:7/25/2008)...y 25 /PRNewswire/ -- AutoGenomics, Inc. today,anno...n Form S-1 with the,Securities and Exchange Commis...ing of shares of its common stock. The number of s...are expected to be offered by,AutoGenomics, Inc., ... been,determined., J.P. Morgan Securities Inc. is...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...ng 20 paintings by renowned masters like M.F. Husa...ment a similar theme to be etched out at Sunday's ...Week. "There are different kinds of desire in a h... fulfilled, some only dream about it. But it's som...
...n people as young as 16 whereas the phenomenon onc... says. "Nobody can escape stress in modern day li...cts like a male hormone and causes the thinning of... Shah said. "Initially, we used to see this begin...
...Saturday in Burhanpur district of Madhya Pradesh i...Maharashtra testing positive for the deadly bird f...ation will also be paid to 323 affected poultry ow...cted," said Rajesh Rajora, commissioner of the sta...
...University are pumping for a controversial theory,...e forced// into "dark states" where they can be ea... idea appears to contravene some of the most accep...y, not long ago dismissed as impossible by much of...
Other Medicine News:Health News:India Fashion Week Reveals - 'The Story Of Desire' 2Health News:Stress Can Cause Hair loss at 16 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 3
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: